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Abstract. The Sleeping Beauty transposon system is used as 
a tool for insertional mutagenesis and oncogenesis. However, 
little is known about the exact histological phenotype of the 
tumors induced. Thus, we used immunohistochemical markers 
to enable histological identification of the type of tumor induced 
by subcutaneous injection of the HRAS, c-Myc and shp53 
oncogenes in female C57BL/6 mice. The tumor was removed 
when it reached 100 mm3 in volume. Subsequently, we used 13 
immunohistochemical markers to histologically identify the 
tumor type. The results suggested that the morphology of the 
tumor was similar to that of sarcomatoid carcinoma.
Introduction
The Sleeping Beauty (SB) system is a genetically engi-
neered insertional mutagenesis system that consists of two 
components: a transposon, which is a series of DNA mobile 
elements flanked by indirect repeat sequences, and SB trans-
posase, which catalyzes the mobilization and reintegration of 
transposon into mouse genomic DNA (1,2). Integration into 
the host chromosome provides prolonged expression of the 
transgene. In addition, the SB system has the advantages of 
both viral and non-viral vector systems (3). For this reason, 
the SB system has attracted much attention as a promising 
delivery system, as well as a discovery tool for cancer-associ-
ated genes. Its ability to achieve long-term in vivo expression 
suggests that the somatic integration of oncogenes using SB is 
a feasible approach to the development of molecularly defined 
tumorigenic mouse models (4). Although xenograft models 
and genetically engineered mice are able to mimic human 
cancer progression (5), the present mouse model systems do 
not correspond to humans with regard to genetic backgrounds 
(i.e., different genetic variants, genetic mutations and subse-
quent protein expression) (6-8). A hallmark of human cancer is 
genetic complexity, meaning a number of different mutations 
are commonly involved (9). The complex genetic altera-
tions in different types of cancer cause various histological 
subtypes and can explain the heterogeneous nature of a given 
neoplasm (9). Carlson et al (4) succeeded in eliciting tumor 
formation in mouse hepatocytes by hydrodynamic injection 
of a transposon containing an activated NRAS oncogene. 
Although those investigators studied the simple feature of the 
tumors induced by insertional mutagenesis, the exact origins 
and tumor subtypes have yet to be determined.
In the present study, the c-Myc, HRAS and shp53 onco-
genes were delivered with SB into C57BL/6 mice. A malignant 
undifferentiated tumor was subsequently identified at the 
injection site on the subcutis of the right side of the lower 
ventral abdominal area. The nature of the tumor was identified 
by histological and immunohistochemical methods (Table I).
Materials and methods
Animals. Female 5-week-old C57BL/6 mice were purchased 
from Orient Bio (Yongin, Korea). The mice were housed at the 
laboratory animal facility at Asan Institute for Life Sciences 
under specific pathogen-free conditions and used according 
to the guidelines of the Institutional Animal Care and Use 
Committee of Asan Institute for Life Sciences.
Plasmid construction. Plasmids encoding the SB trans-
posase (pPGK/SB13) and transposon vectors (PT2/BH) with 
multiple cloning sites between two indirect repeat sequences 
(IR/DRs) were used for this study. Plasmids pPGK/SB13 
and PT2/BH were kind gifts from Drs David Largaespada 
and Perry Hackett at the University of Minnesota. The 
cDNA encoding either c-Myc or HRAS was inserted into the 
pCXEGFP plasmid (kindly provided by Dr Masaru Okabe at 
the Osaka University, Japan) and the transcriptional cassettes 
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were cloned into PT2/BH. PT2/shp53/GFP4, transposon plas-
mids encoding a short hairpin RNA against tumor suppressor 
P53, was a generous gift from Dr John Ohlfest at the University 
of Minnesota. DNA used for injection was prepared using an 
EndoFree Plasmid Maxi kit (cat. no. 12362, Qiagen) according 
to the manufacturer's instructions.
Figure 1. The concept of tumorigenesis using the Sleeping Beauty transposon system. The expressed transposase recognizes the specific sequence of the 
plasmids carrying an oncogene. It cuts and pastes each oncogene into the somatic chromosome, allowing for a longer expression of oncogenes in the host 
tissues. By using this system, tumors with a diverse combination of oncogenes can be readily induced easily.
Figure 2. Development of tumors in female C57BL/6 mice after injection of oncogene plasmid DNA. C57BL/6 mice were coadministered HRAS, c-Myc or 
shp53 oncogene and transposase plasmids subcutaneously. In all the animals (12/12), nodular subcutaneous neoplasms were developed on average 30 days after 
injection. Aggressive growth was observed in each tumor.
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DNA plasmid injections. Animals received a mixture of three 
types of transposon and the plasmid encoding the transposase, 
as detailed above. The molar ratio of transposase-encoding 
plasmids to transposon plasmids was 1:2. First, three types 
of transposon were mixed in equal amounts in total 50 µg 
and then the transposase encoding plasmids was added to 
the transposon mixture with 50 µl of phosphate-buffered 
saline (PBS). The DNA mixture was collected with an insulin 
syringe (31 G) and injected subcutaneously near the right 
inferior mammary gland. Transposon genes and transposase 
were regarded to be 7,000 and 5,000 kb in size, respectively, 
rounded to the nearest kb.
Animal PET imaging
Radiopharmaceutical preparation. Decay-corrected 
radiochemical yields ranged from 60 to 70% and after high-
performance liquid chromatography (HPLC) purification, the 
radiochemical purity was 98±1.2% (mean ± SD). The specific 
activity of the [18F]Flu-deoxy-glucose (FDG) obtained was 
>100 TBq/mmol. PET scans were performed using a microPET 
Focus 120 system (microPET, Concorde Microsystem, Inc.) 
with resolutions of 1.18 (radial), 1.13 (tangential) and 1.44 mm 
(axial) at the center of the field of view. Each mouse was 
injected with 7.4 (0.2 mCi) and 37 MBq (1 mCi) [18F]FDG 
into the tail vein and 10-min static PET scans were obtained. 
Each mouse was maintained under isoflurane anesthesia 
during the uptake and scanning periods. A heating pad and 
heat lamp were used to maintain body temperature at ~37˚C. 
PET images were reconstructed by OSEM2D with a cut-off 
frequency of 0.5 cycles per pixel. No attenuation correction 
was applied.
Tumor monitoring and necropsy. Mice were carefully exam-
ined three times each week to detect tumors. Tumors were 
measured using a digital caliper. The tumor volume (v) in mm3 
was calculated using the formula v = L x W2/2, where L is the 
longest diameter and W is the tumor length that is perpen-
dicular to L. When the tumor reached 100 mm3 in volume, the 
mice were humanely euthanized and subjected to a necropsy 
in which the tumor was excised with the circumferential tissue 
for histopathological examination.
Histology and immunohistochemistry. After macro-
scopic examination, the excised tissues were fixed in 10% 
neutral-buffered formalin. The specimens were embedded 
in paraffin and 3-µm sections were cut and stained using a 
hematoxylin and eosin (H&E) stain. In addition, immuno-
histochemical markers [all from Abcam, (Cambridge, UK)] 
were used to subtype the tumor as follows: CD45 (1:2,000), 
CD163 (1:2,000) and CD68 (1:4,000) for histiocytic sarcoma; 
desmin (1:1,000) and myogenin (1:100) for pleomorphic 
rhabdomyosarcoma; HMB45 (1:1,000) and S100 (1:400) for 
malignant melanoma, α-smooth muscle actin (α-SMA; 1:400) 
for leiomyosarcoma; pan-cytokeratin (1:3,000), cytokeratin 7 
(1:4,000) and cytokeratin 20 (1:2,000) for undifferentiated 
carcinoma; and murine double minute 2 (MDM2; 1:1,000) and 
cyclin-dependent kinase 4 (CDK4; 1:1,000) for pleomorphic 
liposarcoma (Table I).
Detection of the expression of genes. Expression of the c-Myc 
and HRAS genes was identified by immunohistochemistry 
with anti-c-Myc (1:1,000, Abcam) and HRAS (1:1,000, Abcam) 
antibodies, respectively. For the detection of the shp53 gene, an 
anti-GFP antibody (1:4,000, Abcam) was used as a GFP gene 
was contained in the shp53 DNA plasmid as a reporter gene.
Results
Tumor observation. Recipients (12/12) of the three transposons 
and the SB transposase developed single or coupled, nodular, 
subcutaneous neoplasms ~30 days after injection (Fig. 2). Each 
tumor grew rapidly from initial detection to eventually reach 
a large volume.
Animal PET imaging. Different dimensions, both transverse and 
longitudinal, of PET-CT images for subcutaneous neoplasms 
Table I. The immunohistochemical panel.
 Immunostains Type Manufacturer, location Dilution
  1 CD45 M Abcam, Cambridge, UK 1:2,000
  2 CD163 M Abcam, Cambridge, UK 1:2,000
  3 CD68 M Abcam, Cambridge, UK 1:4,000
  4 Desmin M Abcam, Cambridge, UK 1:1,000
  5 Myogenin M Abcam, Cambridge, UK 1:100
  6 Melanoma M Abcam, Cambridge, UK 1:1,000
  7 S100 M Abcam, Cambridge, UK 1:400
  8 α-SMA M Abcam, Cambridge, UK 1:400
  9 Pan-cytokeratin M Abcam, Cambridge, UK 1:3,000
10 Cytokeratin 7 P Abcam, Cambridge, UK 1:4,000
11 Cytokeratin 20 M Abcam, Cambridge, UK 1:2,000
12 MDM2 M Abcam, Cambridge, UK 1:1,000
13 CDK4 M Abcam, Cambridge, UK 1:1,000
M, monoclonal; P, polyclonal; SMA, smooth muscle actin.
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were detected on the injection sites. The tumors are observed 
as a red-pinkish-colored small ball (Fig. 3).
Gross and microscopic findings. A well-demarcated, ovoid 
nodule was located in the subcutaneous soft tissue where the 
Figure 3. PET-CT scan of the tumor. PET-CT images of subcutaneous neoplasm. (A) Longitudinal CT section and (B) transverse CT section. The tumor is 
shown as a red-pinkish-colored small ball (arrows).
Figure 4. Microscopic images of a cut surface of each tumor in H&E staining. (A and B) Tumors had the same histological characteristic including clear 
demarcation, without metastasis (magnification, x20). (C and D) Tumors generally consisted of highly pleomorphic and undifferentiated cells. Some tumors 
resemble epithelial cells, while others resemble mesenchymal cells. (E and F) The poorly differentiated cells were round to oval in shape, with a slightly 
basophilic cytoplasm, oval to elongated hyperchromatic nuclei and prominent nucleoli. Bizarre cells, with large and pale cytoplasm and a more prominent 
nuclei, were observed (magnification, x200).
Figure 5. Pan-cytokeratin immunohistochemistry results of induced tumors. 
Tumors showing positive immunoreactivity to pan-cytokeratin (magni-
fication, x300).
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DNA plasmids were injected. Metastatic foci in non-injected 
sites were not observed. The tumor showed high cellularity 
with abundant mitoses and apoptosis. Both epithelial and 
mesenchymal components were evident. The tumor cells 
were undifferentiated with pleomorphic features character-
ized by round to oval cells with pale basophilic cytoplasm 
and hyperchromatic nuclei with prominent nucleoli (Fig. 4). 
Multinucleated giant cells were occasionally identified. 
Areas of necrosis were also evident in the central part of the 
tumor. However, the overlying skin and its associated adnexa, 
including hair follicles, sebaceous glands and mammary 
glands, did not exhibit dysplastic changes. All the tumors had 
the same morphological features.
Immunohistochemical findings. As summarized in Table II, 
only pan-cytokeratin was found to be positively expressed by 
the tumor cells (Fig. 5), suggesting the epithelial origin of the 
tumor. The other markers were completely negative, except in 
the tumor-associated stroma. Consequently, we diagnosed this 
tumor as a sarcomatoid carcinoma.
Identification of gene expression in the tumor. Expression 
of the c-Myc and HRAS oncogenes was demonstrated by 
immunohistochemical positivity for the c-Myc and HRAS 
antibodies, respectively. A positive signal was detected with an 
anti-GFP antibody, indicating expression of the shp53 DNA.
Discussion
In the present study, we induced tumors in mice via the 
injection of transposons encoding three oncogenes and a 
plasmid-expressing transposase. The histological features of 
the induced tumor were poorly differentiated, thus we used 
immunohistochemical markers to characterize this lesion. 
Multinucleated giant cells were occasionally identified. Areas 
of necrosis were also identified in the central part of the tumor. 
Notably, the tumor expressed only pan-cytokeratin and all 
other markers used in this study were completely negative. As 
a result, we diagnosed the tumor as a sarcomatoid carcinoma.
To the best of our knowledge, there are no spontaneously 
occurring subcutis malignant epithelial tumors that morpho-
logically resemble the tumor induced in this mouse study. 
The origin of this tumor remains unknown as the overlying 
epidermis and associated adnexa were not histologically 
dysplastic. Mammary tissues were also intact and normal 
mammary tissues were embedded within the tumor. This 
finding is consistent with the fact that mammary tissues lack 
response to the SB transposon system. Although this system 
has recently been shown to be able to induce various types of 
SB transposon-induced tumors, certain types of tumors such 
as those of the lung, mammary gland, prostate and pancreas, 
have not yet been generated with the SB transposon system in 
the mouse (10).
As the oncogenes were injected into the subcutis area, the 
origin of the tumor is assumed to be the skin adnexa, although 
this could not be precisely defined. c-Myc overexpression is 
associated with an undifferentiated phenotype in cultured 
astrocytes (11) and gastric carcinomas (12). In addition, c-Myc 
is downregulated during myogenic differentiation (13,14). 
HRAS overexpression is also associated with an anaplastic 
phenotype in mammary adenocarcinomas (15). Therefore, 
we hypothesize that injection of these oncogenes induced the 
growth of tumors with an undifferentiated phenotype.
The tumors induced in this study appeared to be of 
mesenchymal origin morphologically. Features of the tumors 
including undifferentiated pleomorphic cells characterized by 
hyperchromatic nuclei with prominent nucleoli and basophilic 
spindle-shaped cytoplasm resembled sarcomatous tumor. 
However, results of immunohistochemical staining showed 
this tumor to be carcinoma. p53 gene knockout is involved in 
presenting sarcomatoid features, as recent studies showed that 
tumor-suppressor gene mutations within the stroma allowed 
mesenchymal proliferation (16).
Insertional mutagenesis is commonly used in gene discovery 
studies in the field of oncology. This method is easy and more 
rapid compared to conventional genetic engineering (e.g., gene 
knockout). As a result, previous studies have focused on the use 
of the SB transposon system for insertional mutagenesis (17,18). 
However, detailed histological charac terization of the induced 
tumors has not previously been performed. Thus, this study is, 
to the best of our knowledge, the first report of the histological 
and immunohistochemical identification of subcutaneous 
tumors induced by transposable elements.
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